RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Laboratorios Farmaceuticos ROVI Stock

Laboratorios Farmaceuticos ROVI Equity 2024

Laboratorios Farmaceuticos ROVI Equity

539.39 M EUR

Ticker

ROVI.MC

ISIN

ES0157261019

WKN

A0M0GQ

In 2024, Laboratorios Farmaceuticos ROVI's equity was 539.39 M EUR, a 3.73% increase from the 520.01 M EUR equity in the previous year.

Laboratorios Farmaceuticos ROVI Aktienanalyse

What does Laboratorios Farmaceuticos ROVI do?

Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Laboratorios Farmaceuticos ROVI's Equity

Laboratorios Farmaceuticos ROVI's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Laboratorios Farmaceuticos ROVI's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Laboratorios Farmaceuticos ROVI's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Laboratorios Farmaceuticos ROVI's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Laboratorios Farmaceuticos ROVI’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

What is the equity of Laboratorios Farmaceuticos ROVI this year?

Laboratorios Farmaceuticos ROVI has equity of 539.39 M EUR this year.

What was the equity of Laboratorios Farmaceuticos ROVI compared to the previous year?

The equity of Laboratorios Farmaceuticos ROVI has increased/decreased by 3.73% increased compared to the previous year.

What impact does a high equity have on investors of Laboratorios Farmaceuticos ROVI?

A high equity is advantageous for investors of Laboratorios Farmaceuticos ROVI as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Laboratorios Farmaceuticos ROVI?

A low equity can be a risk for investors of Laboratorios Farmaceuticos ROVI, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Laboratorios Farmaceuticos ROVI affect the company?

An increase in equity of Laboratorios Farmaceuticos ROVI can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Laboratorios Farmaceuticos ROVI affect the company?

A reduction in equity of Laboratorios Farmaceuticos ROVI can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Laboratorios Farmaceuticos ROVI?

Some factors that can affect the equity of Laboratorios Farmaceuticos ROVI include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Laboratorios Farmaceuticos ROVI so important for investors?

The equity of Laboratorios Farmaceuticos ROVI is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Laboratorios Farmaceuticos ROVI take to change the equity?

To change equity, Laboratorios Farmaceuticos ROVI can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Laboratorios Farmaceuticos ROVI pay?

Over the past 12 months, Laboratorios Farmaceuticos ROVI paid a dividend of 1.29 EUR . This corresponds to a dividend yield of about 1.74 %. For the coming 12 months, Laboratorios Farmaceuticos ROVI is expected to pay a dividend of 1.69 EUR.

What is the dividend yield of Laboratorios Farmaceuticos ROVI?

The current dividend yield of Laboratorios Farmaceuticos ROVI is 1.74 %.

When does Laboratorios Farmaceuticos ROVI pay dividends?

Laboratorios Farmaceuticos ROVI pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Laboratorios Farmaceuticos ROVI?

Laboratorios Farmaceuticos ROVI paid dividends every year for the past 21 years.

What is the dividend of Laboratorios Farmaceuticos ROVI?

For the upcoming 12 months, dividends amounting to 1.69 EUR are expected. This corresponds to a dividend yield of 2.27 %.

In which sector is Laboratorios Farmaceuticos ROVI located?

Laboratorios Farmaceuticos ROVI is assigned to the 'Health' sector.

Wann musste ich die Aktien von Laboratorios Farmaceuticos ROVI kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Laboratorios Farmaceuticos ROVI from 7/10/2024 amounting to 1.104 EUR, you needed to have the stock in your portfolio before the ex-date on 7/8/2024.

When did Laboratorios Farmaceuticos ROVI pay the last dividend?

The last dividend was paid out on 7/10/2024.

What was the dividend of Laboratorios Farmaceuticos ROVI in the year 2023?

In the year 2023, Laboratorios Farmaceuticos ROVI distributed 0.956 EUR as dividends.

In which currency does Laboratorios Farmaceuticos ROVI pay out the dividend?

The dividends of Laboratorios Farmaceuticos ROVI are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Laboratorios Farmaceuticos ROVI

Our stock analysis for Laboratorios Farmaceuticos ROVI Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Laboratorios Farmaceuticos ROVI Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.